Results 41 to 50 of about 17,461 (174)

Successful use of eculizumab to treat atypical hemolytic uremic syndrome in patients with inflammatory bowel disease

open access: yesThrombosis Journal, 2019
Background Atypical hemolytic uremic syndrome is a rare group of disorders that have in common underlying complement amplifying conditions. These conditions can accelerate complement activation that results in a positive feedback cycle.
Ramy M. Hanna   +8 more
doaj   +1 more source

Pregnancy-associated hemolytic uremic syndrome

open access: yesSaudi Journal of Kidney Diseases and Transplantation, 2020
Pregnancy-associated hemolytic uremic syndrome (P-aHUS) is not an uncommon condition. It is considered a medical emergency that is associated with a high risk of mortality and serious morbidity.
Sami Alobaidi   +4 more
doaj   +1 more source

Micro/nanorobots for detecting and eliminating biological and chemical warfare agents

open access: yesBMEMat, Volume 4, Issue 1, March 2026.
Fuel‐powered and field‐driven micro/nanorobots provide a cutting‐edge platform to safeguard national security and defense. This review reports the latest research progress in micro/nanorobots in sensing and detoxifying biological and chemical warfare agents.
Song Li   +4 more
wiley   +1 more source

Iron, arginine, and redox metabolism in peripheral blood mononuclear cells distinguishes sickle cell disease and pulmonary hypertension

open access: yesHemaSphere, Volume 10, Issue 3, March 2026.
Abstract Pulmonary hypertension (PH) is a severe vascular complication of sickle cell disease (SCD); yet, not all patients with SCD develop PH, and PH also arises independently. This duality underscores the need to understand their intersecting biology.
Francesca I. Cendali   +22 more
wiley   +1 more source

Clostridium septicum Infection and Hemolytic Uremic Syndrome

open access: yesEmerging Infectious Diseases, 1998
Five cases of Clostridium septicum infection secondary to Escherichia coli O157induced hemolytic uremic syndrome have been reported. We report on three cases (one of which is included in the above five) of dual Cl. septicum and E.
M. Barnham, N. Weightman
doaj   +1 more source

Survival and Prognostic Factors of 215 Post‐Transplant Lymphoproliferative Disorders After Solid Organ Transplantations in a Finnish Nationwide Population‐Based Study Over 30 Years

open access: yesHematological Oncology, Volume 44, Issue 2, March 2026.
ABSTRACT Post‐transplant lymphoproliferative disorder (PTLD) is a rare, dreaded complication of organ transplantation with major clinical challenges. We conducted a nationwide population‐based study of all solid organ transplant (SOT) recipients (n = 6555), both adults and children, over a 30‐year period in Finland.
Terhi K. Friman   +11 more
wiley   +1 more source

Primary Thrombotic Microangiopathy in Pediatric Patients

open access: yesGlobal Pediatric Health
Background . Primary thrombotic microangiopathy includes hemolytic uremic syndrome caused by Shiga toxin-producing Escherichia coli , atypical hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Methodology .
Andrés David Aranzazu Ceballos MD   +5 more
doaj   +1 more source

Atypical hemolytic uremic syndrome [PDF]

open access: yesHematology, 2016
AbstractAtypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) that affects multiple organs and the kidneys in particular. aHUS can be sporadic or familial and is most commonly caused by dysregulation of the alternative complement pathway.
openaire   +2 more sources

The Influence of Aerobic and Strength Training on Oxidative Stress and Antioxidant Status in Hemodialysis Patients: A Randomized Controlled Trial

open access: yesHealth Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims To investigate the effects of a 6‐month supervised, personalized combined aerobic and resistance training program on oxidative stress, antioxidant capacity, infection‐related biomarkers, and body composition in maintenance hemodialysis (MHD) patients.
Yuwei Chen   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy